Effect of empagliflozin versus placebo on body composition in patients with acute myocardial infarction and type 2 diabetes mellitus: subgroup analysis of the EMBODY trial
Event: ESC Congress 2020
Topic: Pharmacotherapy
Session: Risk Factors and Prevention ePosters
ESC 365 is supported by
